Safety and efficacy of autologous and allogeneic humanized CD19-targeted CAR-T cell therapy for patients with relapsed/refractory B-ALL

BACKGROUND: Murine chimeric antigen receptor T (CAR-T) cell therapy has demonstrated clinical benefit in patients with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL). However, the potential immunogenicity of the murine single-chain variable fragment domain may limit the persis...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Fengmei, Hu, Yongxian, Zhang, Yanlei, Zhang, Mingming, Yang, Tingting, Wu, Wenjun, Huang, Simao, Xu, Huijun, Chang, Alex H, Huang, He, Wei, Guoqing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9944646/
https://www.ncbi.nlm.nih.gov/pubmed/36808074
http://dx.doi.org/10.1136/jitc-2022-005701

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9944646/
https://www.ncbi.nlm.nih.gov/pubmed/36808074
http://dx.doi.org/10.1136/jitc-2022-005701

Ejemplares similares